Psychiatry/Psychology | Phase I Developments

Psirenity

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CPhI Discover 2021

Participation Not Confirmed

Update your events

Psirenity Granted Approval to Conduct Jamaica’s First Psilocybin Clinical Trial to Help Manage Depression

Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 29, 2021

Details:

The trial is aimed at assessing the safety, tolerability and pharmacokinetics of two unique psilocybin micro-dose products developed by the Psirenity team in the management of mild to moderate depression.

PsyBio Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CPhI Discover 2021

Participation Not Confirmed

Update your events

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

Lead Product(s): Norbaeocystin

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Advanced Biofuels

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 23, 2021

Details:

Norbaeocystin is an analogue of psilocybin and is not a controlled substance. The Company has commenced Phase I of this process, including analytical chemistry technical transfer to establish detection methods for fermentation products and key feedstocks and metabolites.

Perception Neuroscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CPhI Discover 2021

Participation Not Confirmed

Update your events

Perception and Otsuka Enter Collaboration and Licensing Deal for Depression Drug Candidate

Lead Product(s): Arketamine

Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Otsuka Pharmaceutical

Deal Size: Undisclosed Upfront Cash: $20.0 million

Deal Type: Collaboration March 16, 2021

Details:

Under the terms of the license, Otsuka will have exclusive rights to develop and commercialize products containing PCN-101 in Japan. Otsuka will undertake development, regulatory, and commercialization activities in Japan, with input and guidance from both companies.